Trending...
- City Council invites community engagement: Volunteer for Colorado Springs Boards, Commissions, and Committees
- Colorado Springs: Summer Sunrise Openings on Pikes Peak – America's Mountain
- Colorado Springs: Phil Long Dealerships donates $10,000 to City's Keep It Clean COS initiative
ENGLEWOOD, Colo., Nov. 23, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call with its CEO and Chairman, Michael Martino, who will provide a corporate and business on Wednesday, December 1, 2021, at 4:30 pm EDT/ 2:30 pm MT.
Conference Call & Webcast
Wednesday, December 1, 2021, 4:30 pm EDT / 2:30 pm MT
Webcast Link (listen only):
https://event.on24.com/wcc/r/3543501/784479B739F2EB467C477016E7FAD06A
Please note that the webcast and conference call line will be listen only mode and we will not be taking any questions.
More on Colorado Desk
The conference call and webcast can also be accessed from the Investor Relations section of the Company's website at www.ampiopharma.com and will be archived there shortly after the live event.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company primarily focused on the advancement of immunology-based therapies to treat prevalent inflammatory conditions for which there are limited treatment options. Ampio's lead drug, Ampion™, is backed by an extensive patent portfolio with intellectual property protection extending through 2037 and may be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the Biologics Price Competition and Innovation Act (BPCIA).
Forward Looking Statements
Ampio's statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's expectations with respect to Ampion and its classification, as well as those associated with regulatory approvals and other FDA decisions, the Biological License Application (BLA), the ability of Ampio to enter into partnering arrangements, clinical trials and decisions and changes in business conditions and similar events, the ability to receive regulatory approval to conduct clinical trials, that Ampion may be used to treat ARDS induced by COVID-19, all of which are inherently subject to various risks and uncertainties. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and other documents filed with the Securities and Exchange Commission. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.
More on Colorado Desk
Investor Relations
Daniel G. Stokely
[email protected]
720-437-6500
SOURCE Ampio Pharmaceuticals, Inc.
Conference Call & Webcast
Wednesday, December 1, 2021, 4:30 pm EDT / 2:30 pm MT
Webcast Link (listen only):
https://event.on24.com/wcc/r/3543501/784479B739F2EB467C477016E7FAD06A
Conference Call (listen only) | |
Canada dial-in number (Toll Free): | 1 833 950 0062 |
Canada dial-in number (Local): | 1 226 828 7575 |
United States: | 1 844 200 6205 |
United States (Local): | 1 646 904 5544 |
All other locations: | 1 929 526 1599 |
Access code: | 948260 |
*Participants will need to enter the participant access code before being met by an operator |
Please note that the webcast and conference call line will be listen only mode and we will not be taking any questions.
More on Colorado Desk
- FloWater Gets Naked: New Campaign Strips Down the Dirty Truth About What's in Your Water
- New for Sonbuoy Electronics Improved Performance, smaller size, lower cost and weight
- $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
- $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group
The conference call and webcast can also be accessed from the Investor Relations section of the Company's website at www.ampiopharma.com and will be archived there shortly after the live event.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company primarily focused on the advancement of immunology-based therapies to treat prevalent inflammatory conditions for which there are limited treatment options. Ampio's lead drug, Ampion™, is backed by an extensive patent portfolio with intellectual property protection extending through 2037 and may be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the Biologics Price Competition and Innovation Act (BPCIA).
Forward Looking Statements
Ampio's statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's expectations with respect to Ampion and its classification, as well as those associated with regulatory approvals and other FDA decisions, the Biological License Application (BLA), the ability of Ampio to enter into partnering arrangements, clinical trials and decisions and changes in business conditions and similar events, the ability to receive regulatory approval to conduct clinical trials, that Ampion may be used to treat ARDS induced by COVID-19, all of which are inherently subject to various risks and uncertainties. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and other documents filed with the Securities and Exchange Commission. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.
More on Colorado Desk
- New Collaboration Launches Corporate ESG Solution for Responsible Decommissioning and Transparent Reporting
- OtterBox Unveils Summer's Must-Have Threads with New Cactus Leather Embroidery Cases
- SlickCashLoan Launches Free Loan Calculator to Help You Plan Monthly Payments
- Bed Bugs Exterminator at Your Service!
- TikTok Star ArcadeFriends Attempts 24-Hour Claw Machine Marathon at Lucky Puppy Arcade in Las Vegas
Investor Relations
Daniel G. Stokely
[email protected]
720-437-6500
SOURCE Ampio Pharmaceuticals, Inc.
Filed Under: Business
0 Comments
Latest on Colorado Desk
- The Citizens Commission on Human Rights Annual Purple Heart Day Event will be Hosted at the Historic Fort Harrison
- Blake Harris the Leading Authority in International Asset Protection Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- Psychedelics for Vets? CCHR Cites History of Exploitation and Failed Science
- Injured at Work? Local Workers' Comp Attorneys in Grand Junction Offer Free Consultations
- What Makes Apple Grove Dental a Trusted Name for Dental Implants in Colorado Springs
- GreenPal Empowers Lawn Care Pros Leveraging AI, Surpasses 5 Million Transactions
- Colorado: Governor Polis Verbally Declares Disaster Declaration For Wildfires in Montrose, Delta and Mesa County
- Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
- Chaddrick Thomas Launches Two Inspiring New Podcasts:
- Dr. Gregory A. Thomas Launches Bold New Podcast, Real Talk with Dr. Gregory A. Thomas
- Colorado Springs celebrates one year of Pikes Peak Rising, a community-powered movement for mental health
- Colorado Springs: Ramona Avenue at South Nevada Avenue to close on Monday
- Colorado Springs: Northbound Tejon Street to reopen on block downtown
- City of Colorado Springs, El Paso County invite public to open houses for Housing Needs Assessment
- Colorado Springs: Did you know? — Evergreen Cemetery's Roses
- The Blue Luna Encourages Local Schools to Take Steps to Enhance Safety for Students and Staff
- The Sessions Studios Secures $300 Million Commitment to Launch World-Class Studio and 15-Film Global Slate
- Smart Resnse Unveils Smart Resnse(SRMS) Token-Powered AI Orchestration Platform to Revolutionize Multi-Billion Dollar Market
- Josh and Heidi Follow Up the Much Anticipated and Successful Launch of the "Spreading the Good BUZZ" Podcast with a Personal Request
- Revolutionary Blockchain Platform Okh Finance Announces Okh Finance(OKKH) Token Launch to Transform Global Asset Leasing Market